Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises

Bulletin Express06-03 16:45

Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises.

• Issued Share Capital The company’s issued ordinary shares rose by 179,252 to 1,298.41 million. No treasury shares were held, so total issued shares match outstanding shares.

• Source of New Shares – Pre-IPO Share Option Plan: 38,000 shares exercised. – Post-IPO Share Option Plan: 141,252 shares exercised. These exercises generated HKD 59,835.27 in proceeds.

• Authorised Capital and Public Float Authorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 200,000. Clover confirmed compliance with the Main Board’s minimum 25% public-float requirement.

• Other Instruments No activity was reported for warrants, convertibles, depositary receipts or other equity-linked instruments during the month.

The filing indicates routine capital expansion through employee incentives, with no impact on the overall authorised limit or float sufficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105680932?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-03 16:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105680932","market":"hk","top_or_hot":-1,"title":"Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises","media":"Bulletin Express","content":"<p>Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises.</p>\n<p>• Issued Share Capital  \nThe company’s issued ordinary shares rose by 179,252 to 1,298.41 million. No treasury shares were held, so total issued shares match outstanding shares.</p>\n<p>• Source of New Shares  \n– Pre-IPO Share Option Plan: 38,000 shares exercised.  \n– Post-IPO Share Option Plan: 141,252 shares exercised.  \nThese exercises generated HKD 59,835.27 in proceeds.</p>\n<p>• Authorised Capital and Public Float  \nAuthorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 200,000. Clover confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>• Other Instruments  \nNo activity was reported for warrants, convertibles, depositary receipts or other equity-linked instruments during the month.</p>\n<p>The filing indicates routine capital expansion through employee incentives, with no impact on the overall authorised limit or float sufficiency.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Biopharmaceuticals Issues 0.18 Million New Shares in May on Option Exercises\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-03 16:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises.</p>\n<p>• Issued Share Capital  \nThe company’s issued ordinary shares rose by 179,252 to 1,298.41 million. No treasury shares were held, so total issued shares match outstanding shares.</p>\n<p>• Source of New Shares  \n– Pre-IPO Share Option Plan: 38,000 shares exercised.  \n– Post-IPO Share Option Plan: 141,252 shares exercised.  \nThese exercises generated HKD 59,835.27 in proceeds.</p>\n<p>• Authorised Capital and Public Float  \nAuthorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 200,000. Clover confirmed compliance with the Main Board’s minimum 25% public-float requirement.</p>\n<p>• Other Instruments  \nNo activity was reported for warrants, convertibles, depositary receipts or other equity-linked instruments during the month.</p>\n<p>The filing indicates routine capital expansion through employee incentives, with no impact on the overall authorised limit or float sufficiency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1105680932","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105680932","pubTimestamp":1780476317,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises. • Issued...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"三叶草生物制药5月份因期权行权发行18万股新股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals, Ltd. (Clover) filed its Monthly Return for the period ended 31 May 2026, detailing a marginal increase in share capital driven solely by employee option exercises.\n• Issued Share Capital  \nThe company’s issued ordinary shares rose by 179,252 to 1,298.41 million. No treasury shares were held, so total issued shares match outstanding shares.\n• Source of New Shares  \n– Pre-IPO Share Option Plan: 38,000 shares exercised.  \n– Post-IPO Share Option Plan: 141,252 shares exercised.  \nThese exercises generated HKD 59,835.27 in proceeds.\n• Authorised Capital and Public Float  \nAuthorised share capital remained unchanged at 2.00 billion ordinary shares with a par value of USD 0.0001, equivalent to USD 200,000. Clover confirmed compliance with the Main Board’s minimum 25% public-float requirement.\n• Other Instruments  \nNo activity was reported for warrants, convertibles, depositary receipts or other equity-linked instruments during the month.\nThe filing indicates routine capital expansion through employee incentives, with no impact on the overall authorised limit or float sufficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105680932","isCrawlerRequest":true}